Navigation Links
Asymmetrex Intensifies Campaign to Increase Awareness of the Adult Tissue Stem Cell Counting Problem

Since September of this year, stem cell biotechnology company Asymmetrex has been leading a campaign to increase awareness of the adult tissue stem cell counting problem in stem cell medicine and the stem cell supply industry. During the month of November, the company is intensifying this effort with new educational publications and presentations at clinical trial supply conferences, at meetings of standards development agencies, and at university laboratories.

“The greatest barrier to progress in stem cell medicine is not the lack of a means to count adult tissue stem cells,” corrects James L. Sherley, M.D., Ph.D., founder and director of Asymmetrex. “Instead, the more debilitating barrier is the presently poor awareness that the problem exists. Even experts in many disciplines of stem cell research and stem cell medicines think we can, or act as if we can, count therapeutic tissue stem cells. But in reality, no previously used method can count tissue stem cells accurately.”

During the month of November, Sherley is undertaking several endeavors to increase awareness of the tissue stem cell counting problem, which he defines as a problem that Asymmetrex has now solved with its recently introduced AlphaSTEM Test™ service, which provides specific and accurate counting of stem cells from any perinatal or postnatal organs and tissues. At November events, Sherley intends to continue focusing on increasing awareness and understanding of the long-standing unmet need for a means to count tissue stem cells.

On November 6, Sherley delivered a lecture at the 2018 10th Annual Outsourcing Clinical Trials New England Conference in Boston to relate how the need for stem cell counting impacts the regulatory landscape for supplying tissue stem cells to clinical trials. On November 8, he will introduce the AlphaSTEM Test™ to attendees at the American Society for Testing and Materials International 2018 Committee Week in Washington, DC to begin a discussion of developing standards for tissue stem cell counting and dose determination. Later in Boston, on November 14-15 at the 2018 3rd Annual Preclinical Development Operations Summit, he will discuss the need for development and adoption of an industry-wide regulatory standard for tissue stem cell counting, dose determination, and stem cell supply quality control.

To further illuminate the challenges of the poor level of awareness of the tissue stem cell counting problem, in an invited essay published November 6 on the Arena International Clinical Trials Supply website, Sherley compares the present state of the industry’s treatment of the issue to the Hans Christian Andersen fairy tale the Emperor’s New Clothes. He argues that, for the stem cell industry, the debilitating consequences of this situation are more than just a fairy tale.

In the Andersen story, swindlers convince a town’s emperor that they can weave fabrics so finely that they will be invisible to anyone who is stupid or unfit for their position. The emperor empties out the town treasury to pay to have clothes made from these remarkable linens. Of course, the swindlers weave only air and outfit the emperor with nothing at all, leaving him to walk about in only his undergarments. Fearing possible discovery as being stupid and unfit, the emperor’s most trusted advisors, also seeing nothing, join the emperor’s feigned amazement and praise garments that are not there. When a young boy speaks honestly about seeing the emperor parading down the street in his underwear, the townspeople acknowledge the deception; but the emperor and his elite courtiers persist in their pretense to avoid further embarrassment.

Sherley writes, “In the [stem cell industry], quantification of adult tissue stem cells has been the emperor’s new clothes for many years.” Though many in the industry are misinformed about, or unaware of the need for stem cell counting, there are many industry leaders who perpetuate the myth that it is possible to count tissue stem cells either knowingly or unwittingly. Sherley points out that an internet search will identify many examples of claims of tissue stem cell counting, tissue stem cell assays, tissue stem cell dose, and tissue stem cell reagents that the authors could not possibly know to be true, because they have not counted tissue stem cells specifically…yet. This is the limiting state of affairs that Asymmetrex is working to change with its first-in-kind technology for counting adult tissue stem cells.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations.

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology technology :

1. Asymmetrex Starts New Campaign for Greater Awareness of the Importance of Counting Tissue Stem Cells
2. Asymmetrex Introduces New Contract Service For Producing Greater Numbers of Therapeutic Adult Tissue Stem Cells at Reduced Cost
3. Asymmetrex’s New Patent Issued for Counting and Evaluating Therapeutic Adult Tissue Stem Cells Also Supports Company’s New Stem Cell Production Services
4. Asymmetrex Will Join RegMedNet Panel to Discuss New Developments in Regulatory Policies for Stem Cell Medical Research
5. Asymmetrex Director Comments on Positive Attributes of Private Stem Cell Clinics
6. Asymmetrex Named One of the "50 Most Valuable Brands of the Year 2017" by The Silicon Review
7. Asymmetrex Presents Adult Tissue Stem Cell Counting at the Alliance for Regenerative Medicine’s First Partnering Conference, May 22-23
8. At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific Quality Control Test for Therapeutic Tissue Stem Cells
9. Asymmetrex’s Head Will Lead Discussion on Supplying Private Stem Cell Clinics at the 6th Annual Clinical Trial Supply New England 2017 Conference in Boston
10. Asymmetrex's AlphaSTEM Test Adult Tissue Stem Cell Counting Technology Established to Be a Leading Interest for Regenerative Medicine in 2016
11. Asymmetrex Director Shares Vision for Company and Private Stem Cell Treatment Clinics in Two Arena International Event Group Forums
Post Your Comments:
(Date:5/31/2019)... California (PRWEB) , ... May ... ... of our patent applications from the USPTO providing proprietary interest to our ... METHOD FOR SLEEP DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object Pharma, Inc., a ... acquisition of Metabiologics, Inc., a globally recognized leader in the production and sale ... rights to a full spectrum of botulinum neurotoxins, as well as a CDC ...
(Date:5/22/2019)... ... ... Artemis (formerly Agrilyst), the leading enterprise Cultivation Management Platform (CMP), today ... Astanor Ventures and Talis Capital with participation from existing investors New ... company has raised $11.75m to date and will use the new funding to rapidly ...
(Date:5/15/2019)... ... May 15, 2019 , ... Milton Hershey School® has ... for his work within the biomedical industry, where he is changing lives by creating ... , “William Harding epitomizes the vision of our founders – Milton and Catherine ...
Breaking Biology Technology:
(Date:6/19/2019)... VEGAS (PRWEB) , ... June 19, 2019 , ... Dahryn ... improving physicochemical properties of Cefazolin Sodium, antibiotic which can prove to be beneficial for ... Over 519% increase in residue amount , Over 68% decrease in weight ...
(Date:6/16/2019)... ... 2019 , ... Emtec, Inc.®, a global IT and management ... Versiti’s CIO at the Healthcare Industry User Group (HIUG) Interact 2019 ... Vice President and Chief Information Officer, Lynne Briggs, will present Versiti’s Oracle Cloud ...
(Date:6/13/2019)... ... June 13, 2019 , ... Global Clinical ... serving the end-to-end clinical and ancillary supply chain management needs of large- and ... research organizations, today announced it will sponsor a summer education program offered by ...
Breaking Biology News(10 mins):